Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease

We review the cases of 31 patients with stage IVb or recurrent cervical ade nocarcinoma who were treated with combination chemotherapy utilizing mitomy cin C, etoposide, and cisplatin (MEP). The total response rate was 16.1% (9 5% confidence intervals (CIs), 5.5 to 33.7%) with 4 patients having a compl ete response (CR) and 1 having a partial response. In patients with no prio r chemotherapy, the response rate was 26.7% (95% CIs, 7.8 to 55.1%) with 2 of these CR patients surviving over 3 years, 1 a disease-free survival, A m arked response was found in distant recurrent lesions. The major toxicity w as myelosuppression. Forty-five percent of patients I-rad leukocytopenia ab ove grade 3; thrombocytopenia and anemia were not common. In patients with cervical adenocarcinoma and no prior chemotherapy, there was a moderate res ponse to MEP therapy. (C) 1999 Academic Press.